Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML

Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML

Abstract Chemotherapy resistance is the main impediment in the treatment of acute myeloid leukaemia (AML). Despite rapid advances, the various mechanisms inducing resistance development remain to be defined in detail. Here we report that loss-of-function mutations (LOF) in the histone methyltransfer...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Julia M. Kempf, Sabrina Weser, Michael D. Bartoschek, Klaus H. Metzeler, Binje Vick, Tobias Herold, Kerstin Völse, Raphael Mattes, Manuela Scholz, Lucas E. Wange, Moreno Festini, Enes Ugur, Maike Roas, Oliver Weigert, Sebastian Bultmann, Heinrich Leonhardt, Gunnar Schotta, Wolfgang Hiddemann, Irmela Jeremias, Karsten Spiekermann
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/0a2238e6e69947ba9113af2e76fa12bb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/0a2238e6e69947ba9113af2e76fa12bb

Ejemplares similares